Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Tran Ngoc Huu, Nguyen Trong Toan, Ha Manh Tuan, Ho Lu Viet, Pham Le Thanh Binh, Ta-Wen Yu, Fakrudeen Shafi, Ahsan Habib, Dorota Borys
Author Information
Tran Ngoc Huu: Pasteur Institute Ho Chi Minh City, 167 Pasteur Street District, 3 Ho Chi Minh City, Vietnam. tnhuu@pasteur-hcm.org.vn
BACKGROUND: Pneumococcal infections are major causes of child mortality and morbidity worldwide and antibiotic resistance of Streptococcus pneumoniae is a major concern, especially in Asian countries. The present study was designed to evaluate the reactogenicity and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the licensed diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliovirus and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib) in a 3-dose primary vaccination course in Vietnamese infants. METHODS: This phase III, open, randomised study was conducted in one centre in Ho Chi Minh City between February and July 2011. Healthy infants (N=300) were randomised (2:1) to receive either PHiD-CV co-administered with DTPa-HBV-IPV/Hib (PHiD-CV group) or DTPa-HBV-IPV/Hib alone (Control group) at 2, 3, and 4 months of age. RESULTS: Within 31 days post-vaccination, 8.2% of overall doses in the PHiD-CV group and 3.0% of overall doses in the Control group were followed by at least one solicited and/or unsolicited, local and/or general adverse event of grade 3 intensity. Pain at injection site was the most common grade 3 solicited symptom, which was reported following 6.5% and 1.0% of overall doses in the PHiD-CV and Control groups, respectively. Within 4 days post-vaccination, the most common solicited local and general symptoms reported with any intensity were pain (48.9% and 31.0% of doses in the PHiD-CV and Control groups) and irritability (58.0% and 40.4% of doses in the PHiD-CV and Control groups). Within 31 days post-vaccination, the incidence of unsolicited symptoms was comparable in both groups (following 12.3% and 14.8% of doses in the PHiD-CV and Control groups, respectively). Throughout the study, 13 serious adverse events (SAEs) were reported in 9 infants in the PHiD-CV group and 11 SAEs in 6 infants in the Control group. None of them were fatal or considered causally related to vaccination. CONCLUSIONS: PHiD-CV had a clinically acceptable safety profile when co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants. The reactogenicity of PHiD-CV was comparable to that observed in other South-East Asian populations.
Associated Data
ClinicalTrials.gov | NCT01153841
References
Lancet. 2010 Jun 5;375(9730):1969-87
[PMID: 20466419]
Pediatr Infect Dis J. 2009 Oct;28(10):e276-82
[PMID: 20118683]
Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S66-76
[PMID: 19325449]
Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88
[PMID: 19325450]
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S57-64
[PMID: 19191620]
Pediatr Infect Dis J. 2000 Mar;19(3):187-95
[PMID: 10749457]
Vaccine. 2003 May 16;21(17-18):2003-14
[PMID: 12706690]
Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S89-96
[PMID: 19325451]
